
## Human FcRH5/FcRL5 Protein

## Cat. No. FCR-HM401

## ϗͺϒͺϿ·ϽϨ


Description	
Source	Recombinant Human FcRH5/FcRL5 Protein is expressed from HEK293 with His tag and Avi tag at the N- Terminus.
	It contains GIn16-Gly851.
Accession	Q96RD9-1
Molecular Weight	The protein has a predicted MW of 94.2 kDa. Due to glycosylation, the protein migrates to 95-115 kDa based on Bis-Tris PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Bis-Tris PAGE
Formulation and S	torage
Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before Iyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt80°C for 3 months after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background	
	FcRH5 is a cell surface marker enriched on malignant plasma cells when compared to other hematologic malignancies and normal tissues. DFRF4539A is an anti-FcRH5 antibody-drug conjugated to monomethyl auristatin E (MMAE), a potent anti-mitotic agent.
Assay Data	



Human FcRH5 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ELISA Data

Human FcRH5, His Tag ELISA 0.5µg Human FcRH5, His Tag Per Well



Immobilized Human FcRH5, His Tag at 5µg/ml (100µl/Well) on the plate. Dose response curve for Anti-FcRH5 Antibody, hFc Tag with the EC50 of 19.1ng/ml determined by ELISA.